These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32882043)

  • 1. Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral Human Immunodeficiency Virus Preexposure Prophylaxis: A Mathematical Model.
    Maloney KM; Le Guillou A; Driggers RA; Sarkar S; Anderson EJ; Malik AA; Jenness SM
    J Infect Dis; 2021 Jan; 223(1):72-82. PubMed ID: 32882043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study.
    Marshall BDL; Goedel WC; King MRF; Singleton A; Durham DP; Chan PA; Townsend JP; Galvani AP
    Lancet HIV; 2018 Sep; 5(9):e498-e505. PubMed ID: 29908917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing Preferences for Long-Acting Injectable Pre-Exposure Prophylaxis Among Young Adult Sexual Minority Men and Transgender Women.
    Weeden T; Garofalo R; Johnson AK; Schnall R; Cervantes M; Scherr T; Kuhns LM
    Acad Pediatr; 2024; 24(7):1110-1115. PubMed ID: 38631476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021-2022: cross-sectional study.
    Schoenberg P; Edwards OW; Merrill L; Martinez CA; Stephenson R; Sullivan PS; Jones J
    J Int AIDS Soc; 2023 Mar; 26(3):e26077. PubMed ID: 36951057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Willingness to Use Long-Acting Injectable PrEP Among PrEP Naïve Black and Hispanic Sexual Gender Minority Persons.
    Okafor CN; Eaton L; Watson R
    AIDS Behav; 2024 Jun; 28(6):2166-2174. PubMed ID: 38526639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations from Black and Latinx sexual minority males to include pharmacists to increase greater accessibility and OnlyFans stars to promote uptake of injectable PrEP.
    Washington TA; Applewhite S; Green Y; Malone N; Barreras J
    J Am Pharm Assoc (2003); 2024; 64(5):102153. PubMed ID: 38960023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will Gay and Bisexual Men Taking Oral Pre-exposure Prophylaxis (PrEP) Switch to Long-Acting Injectable PrEP Should It Become Available?
    John SA; Whitfield THF; Rendina HJ; Parsons JT; Grov C
    AIDS Behav; 2018 Apr; 22(4):1184-1189. PubMed ID: 28913659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Willingness to take long-acting injectable pre-exposure prophylaxis among men who have sex with men who participated in the CROPrEP study: a cross-sectional online study.
    Liu Y; Chu Z; Wang H; Huang X; Chen Y; Wang H; Zou D; Jiang Y; Geng W; Hu Q; Zhou B; Shang H
    BMC Public Health; 2023 Dec; 23(1):2494. PubMed ID: 38093204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S.
    Parsons JT; Rendina HJ; Whitfield TH; Grov C
    AIDS Behav; 2016 Jul; 20(7):1390-9. PubMed ID: 27000145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interest in Long-Acting Injectable PrEP in a Cohort of Men Who have Sex with Men in China.
    Meyers K; Wu Y; Qian H; Sandfort T; Huang X; Xu J; Zhang J; Xia W; Glidden D; Wu H; Shang H
    AIDS Behav; 2018 Apr; 22(4):1217-1227. PubMed ID: 28707025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men.
    Patel RR; Crane JS; López J; Chan PA; Liu AY; Tooba R; James AS
    PLoS One; 2018; 13(12):e0209484. PubMed ID: 30592756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projected Impact of Expanded Long-Acting Injectable PrEP Use Among Men Who Have Sex With Men on Local HIV Epidemics.
    Balasubramanian R; Kasaie P; Schnure M; Dowdy DW; Shah M; Fojo AT
    J Acquir Immune Defic Syndr; 2022 Oct; 91(2):144-150. PubMed ID: 35636746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.
    Meyers K; Rodriguez K; Moeller RW; Gratch I; Markowitz M; Halkitis PN
    PLoS One; 2014; 9(12):e114700. PubMed ID: 25502768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intention and preference to use long-acting injectable PrEP among MSM in the Netherlands: a diffusion of innovation approach.
    Wang H; Zimmermann HML; van de Vijver D; Jonas KJ
    AIDS Care; 2024 Jul; 36(sup1):89-100. PubMed ID: 38713631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia.
    Paudel K; Gupta S; Gautam K; Wickersham JA; Khati A; Azwa I; Ha T; Shrestha R
    J Community Health; 2023 Jun; 48(3):513-521. PubMed ID: 36732459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Willingness of community-recruited men who have sex with men in Washington, DC to use long-acting injectable HIV pre-exposure prophylaxis.
    Levy ME; Patrick R; Gamble J; Rawls A; Opoku J; Magnus M; Kharfen M; Greenberg AE; Kuo I
    PLoS One; 2017; 12(8):e0183521. PubMed ID: 28827821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To switch or not to switch: Intentions to switch to injectable PrEP among gay and bisexual men with at least twelve months oral PrEP experience.
    Meyers K; Wu Y; Brill A; Sandfort T; Golub SA
    PLoS One; 2018; 13(7):e0200296. PubMed ID: 30024903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Perceived Added Value of Bimonthly Injectable Pre-Exposure Prophylaxis According to West African Men Who Have Sex with Men: A Focus Group Study.
    Reyniers T; Fiorentino M; Babo SAY; Ouedraogo M; Kanta I; Agbegnigan LE; Rojas D; Anoma C; Dah TTE; Mensah E; Keita BD; Spire B; Vuylsteke B; Laurent C
    AIDS Patient Care STDS; 2023 Oct; 37(10):480-488. PubMed ID: 37862074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
    Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
    Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Determinants and Implementation Strategies to Increase Long-Acting Injectable PrEP for HIV Prevention Among Latino Men Who Have Sex with Men (MSM).
    Zapata JP; Zamantakis A; Queiroz AAFLN
    J Racial Ethn Health Disparities; 2024 Aug; 11(4):2093-2102. PubMed ID: 37347407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.